Eli Lilly & Co. announced Wednesday that it will reduce prices for some of its older insulins and expand a cap on costs insured patients pay when they fill prescriptions, providing critical relief to people with diabetes who can face annual costs of more than $1,000 for insulin. The drugmaker said the cap on out-of-pocket costs will take effect immediately, though the high cost of insulin in the U.S. is still a major issue.
Posts tagged as “Eli Lilly’”
Eli Lilly has announced a 70% price cut for its most commonly used forms of insulin, with a list price of $25 a vial as of May 1, and out-of-pocket costs capped at $35 a month for those with commercial insurance. The move comes in response to criticism of insulin prices, which have led to rationing and other health risks for those with diabetes. Eli Lilly is also expanding its Insulin Value Program to help make insulin more accessible and affordable.